Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

For the first time, scientists have confirmed a neurobiochemical link between dopamine and cognitive flexibility, according ...

Theranocure Co. Ltd. has prepared and tested new vanillic acid derivatives targeting the dopamine D1 receptor (D1R) reported to be useful for the treatment of neuroinflammation and Alzheimer’s disease ...

"Renal-dose" dopamine is widely used in clinical practice despite the controversial benefit in the prophylaxis and treatment of acute renal failure. Goldberg et al. [1] were the first to ...

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor antagonist for patients with Tourette syndrome. Emalex Biosciences announced ...

"Our results indicate that loss of BBS-1 in worm dopamine neurons results in excess ... carry the proper number and kinds of ...

One of the main treatments for movement disorders is a group of drugs called dopamine-receptor agonists, which include ...

a novel dopamine-1 receptor antagonist, in subjects with Tourette syndrome. The company will meet with the Food and Drug Administration and other global health authorities to discuss the ...

Increasing calcium restored dopamine release, showing that the problem lies in nicotinic receptor function. "Our findings suggest that behavioral inflexibility in autism arises from deficits in ...